Login to Your Account



Regeneron's Eylea Gets Backing of FDA Panel

By Mari Serebrov


Monday, June 20, 2011
Regeneron Pharmaceuticals Inc. sold an FDA advisory committee on the benefits of its Eylea as an every-other-month treatment for the neovascular form of age-related macular degeneration (wet AMD).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription